Tumor Necrosis Factor Alpha (TNF

Most Exhaustive Report

Tumor Necrosis Factor Alpha (TNF-a) Inhibitors - Pipeline Insights 2018

Tumor Necrosis Factor Alpha (TNF

Most Exhaustive Report

Tumor Necrosis Factor Alpha (TNF-a) Inhibitors - Pipeline Insights 2018

SKU : APA17806 Published on : February 2018 Pages : 70

${{licencetype}}

Get 10% Free Customization
On This Report.
Customize this report Enquire before buying
data center market research

Get actionable insights on how COVID-19 is impacting your business sector.

Enquire now

Tumor Necrosis Factor Alpha (TNF-a) Inhibitors - Pipeline Insights 2018

Advent Tumor Necrosis Factor Alpha (TNF-a) inhibitors represent one a major treatment paradigm for inflammatory diseases. Anti TNF-a drug class one of the most commercially successful drug classes in the pharmaceutical industry worldwide. Currently marketed anti-TNF-a drugs are among the top five global block buster drugs.  Cumulative sales of top three TNF-a inhibitors (Remicade, Enbrel, Humira) surpassed $32 billion in 2016.

TNF-a inhibitors exhibit therapeutic efficacy blocking the activity of tumor necrosis factor (TNF), a cytokine that causes inflammation and leads to diverse immune-system diseases. Apparently, almost all the currently marketed TNF-a drugs are indicated for wide spectrum of immune-related disorders such as – Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis and uveitis. Advances in biological research is uncovering further therapeutic benefits of this drug class for wider indications. Currently clinical research is focused on evaluating therapeutic efficacy and safety of TNF-a inhibitors on wide range of other inflammatory diseases, neurodegenerative diseases and multiple cancers.

Reasons to buy

  • To gain erudite insights on TNF-a inhibitor pipeline landscape
  • Ascertain unique product development dynamics and leverage it for novel target identification, drug repositioning and precision medicine.
  • For optimization of pipeline product portfolio in correspondence with ever dynamic pharmaceutical market
  • Identify competitors and design strategic initiatives for drug development activities
  • To understand the market and choose right partners for strategic collaborations
  • To obtain well-informed updates on drug termination/drug discontinuations

FILL IN YOUR DETAILS BELOW TO GET FREE SAMPLE OF THIS REPORT

Client Speak

data center market size

Erik Young

CEO, Co-founder
Audink Inc., DBA Audios

The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow.

data center market

Benjamin Arnold

Senior Product Manager
Interstates

I recently purchased a key Arizton Industry Outlook & Forecast in order to better understand growth for specific market segments and the macro environmental factors impacting this growth. I found Ariztonā€™s coverage of the market dynamics and key takeaways to be insightful and valuable. The segmentation breakouts gave me the information I needed to guide strategic considerations.

data center market research

Hallmann, Nickolai

Manager Market Analyst Power
Generation & Energy
Rolls-Royce Power Systems AG

The provided information by Arizton really met my expectations. Especially the deep information about the datacenter ecosystem was very helpful. Furthermore, I absolutely appreciate the optimal service from the key account managers of Arizton. It was always a pleasure working with them.

Customer Service

Support

+1-312-235-2040

Copyright 2019 - Arizton

data center market